Author

H. Ishigaki

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Assay:proteomics· 3 Organism:mouse· 2 Organism:non-human primate· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

C. T. Nguyen· 4 shared M. Nakayama· 4 shared Y. Itoh· 4 shared Y. Kitagawa· 4 shared K. Hayashi· 2 shared K. Iwatsuki-Horimoto· 2 shared M. Imai· 2 shared M. Ito· 2 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

C. T. Nguyen

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Fc-modified SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models.

M. Takeshita, H. Fukuyama, K. Kamada, T. Matsumoto, C. Makino-Okamura, T. Uchikubo-Kamo, Y. Tomabechi, K. Hanada, S. Moriyama, Y. Takahashi, H. Ishigaki, M. Nakayama, C. T. Nguyen, Y. Kitagawa, Y. Itoh, , T. Takeuchi

The paper develops Fc-modified SARS-CoV-2 neutralizing antibodies effective against variants, showing reduced viral titers and lung damage in animal models.

bioRxiv · Jun 21, 2022 · PreprintMicrobiology

An attenuated vaccinia vaccine encoding the SARS-CoV-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human ACE2 transgenic mice from SARS-CoV-2 and its variants

H. Ishigaki, F. Yasui, M. Nakayama, A. Endo, N. Yamamoto, K. Yamaji, C. T. Nguyen, Y. Kitagawa, T. Sanada, T. Honda, T. Munakata, M. Higa, S. Toyama, R. Kono, A. Takagi, , M. Kohara

This study develops a vaccinia-based vaccine encoding SARS-CoV-2 spike protein that induces broad and durable immunity, protecting against multiple variants in non-human primates and transgenic mice.

bioRxiv · Jun 12, 2022 · PreprintMicrobiology

Optimization of an LNP-mRNA vaccine candidate targeting SARS-CoV-2 receptor-binding domain

K. Kobiyama, M. Imai, N. Jounai, M. Nakayama, K. Hioki, K. Iwatsuki-Horimoto, S. Yamayoshi, J. Tsuchida, T. Niwa, T. Suzuki, M. Ito, S. Yamada, T. Watanabe, M. Kiso, H. Negishi, , K. J. Ishii

This study optimizes an LNP-mRNA vaccine targeting SARS-CoV-2 RBD by removing reactogenic materials, improving immunogenicity and protection in macaques.

bioRxiv · Mar 4, 2021 · PreprintImmunology

Neutralizing antibody-dependent and -independent immune responses against SARS-CoV-2 in cynomolgus macaques

H. Ishigaki, M. Nakayama, Y. Kitagawa, C. T. Nguyen, K. Hayashi, M. Shiohara, B. Gotoh, Y. Itoh

This study examines immune responses in cynomolgus macaques infected with SARS-CoV-2, showing both neutralizing antibodies and IFN-γ-producing T-cells contribute to viral clearance.

bioRxiv · Aug 18, 2020Microbiology